Premium
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, bre... Kairos Pharma is a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma. We are driven by innovative science to develop novel and transformative drug therapies to treat cancer. In June 2021, Kairos acquired Enviro Therapeutics through a share exchange. The acquisition allowed us to incorporate into our company Enviros advanced pipeline of drug candidates in Phase 1 and Phase 2 trials. The pipeline includes two therapeutic agents addressing what we believe to be significant unmet needs in the prostate and lung cancer markets and that we believe can help address cancer progression in those cancers that develop resistance to standard therapies. Show more
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announces that the Company will be presenting a talk during the plenary session of the joint AACR-JCA...
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company developing therapies to surmount current cancer drug resistance and immune suppression, provides an overview...
Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, and Neil Bhowmick, Chief Scientific Officer...
ENV105 can potentially address resistance in a wide range of cancers as they become resistant to standard treatments. Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.17 | -10.7594936709 | 1.58 | 1.64 | 1.4 | 107439 | 1.50264026 | CS |
| 4 | -0.13 | -8.44155844156 | 1.54 | 3.25 | 0.851 | 7164498 | 2.08661806 | CS |
| 12 | 0.01 | 0.714285714286 | 1.4 | 3.25 | 0.851 | 2554314 | 2.08449134 | CS |
| 26 | -2.59 | -64.75 | 4 | 4 | 0.851 | 1541165 | 2.07764159 | CS |
| 52 | -2.59 | -64.75 | 4 | 4 | 0.851 | 1541165 | 2.07764159 | CS |
| 156 | -2.59 | -64.75 | 4 | 4 | 0.851 | 1541165 | 2.07764159 | CS |
| 260 | -2.59 | -64.75 | 4 | 4 | 0.851 | 1541165 | 2.07764159 | CS |
| Symbole | Prix | Vol. |
|---|---|---|
| SOXLDirexion Daily Semiconductor Bull 3X Shares | US$ 27,02 (-0,48%) | 102,26M |
| SPXSDirexion Daily S&P 500 Bear 3X Shares New | US$ 5,82 (1,39%) | 81,08M |
| TSLZT Rex 2X Inverse Tesla Daily Target ETF | US$ 2,3017 (-2,26%) | 75,06M |
| NVDQT Rex 2X Inverse NVIDIA Daily Target ETF | US$ 3,565 (7,70%) | 70,47M |
| SOXSDirexion Daily Semiconductor Bear 3X Shares New | US$ 20,61 (0,73%) | 67,19M |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
